Which is more potent: Spironolactone or Lasix (Furosemide)?

From the Guidelines

Lasix (furosemide) is more potent than spironolactone as a diuretic. According to the study published in 2018 1, furosemide, a loop diuretic, has a rapid onset of action and can cause significant diuresis, whereas spironolactone, an aldosterone antagonist, has a slow onset of action and a milder diuretic effect. The study notes that furosemide can be used to achieve quicker recovery of symptoms and sodium balance in patients with ascites Grade 2 or 3, while spironolactone is often used as the mainstay of diuretic treatment due to its ability to inhibit secondary hyperaldosteronism.

Some key differences between the two diuretics include:

• Mechanism of action: Furosemide acts on the Na-K-2Cl receptors in the thick ascending limb of Henle’s loop, while spironolactone acts as an aldosterone antagonist in the distal tubule.
• Onset of action: Furosemide has a rapid onset of action, while spironolactone requires three to four days to achieve a stable concentration.
• Side effects: Furosemide may cause hypokalemia, while spironolactone may cause hyperkalemia, gynecomastia, mastalgia, hyposexuality, and erectile dysfunction.
• Dosage: The starting dose of furosemide is 20–40 mg/day, with a maximum dose of 160 mg/day, while the starting dose of spironolactone is 50–100 mg/day, with a maximum dose of 400 mg/day.

The study suggests that combination therapy with aldosterone antagonist and loop diuretics can be effective in controlling ascites, with a ratio of 100:40 of spironolactone and furosemide recommended to maintain adequate serum potassium levels 1. However, in terms of potency, furosemide is generally considered more potent than spironolactone, making it a better option for acute situations requiring rapid fluid removal.

From the Research

Potency Comparison of Spironolactone and Lasix (Furosemide)

• The potency of Spironolactone and Lasix (Furosemide) can be compared based on their effects on heart failure and diuretic use.
• A study published in the European journal of heart failure 2 found that Spironolactone reduced heart failure hospitalizations, but its effect could not be solely attributed to potential diuretic effects.
• Another study published in Medicine 3 found that Spironolactone reduced hospitalizations and improved New York Heart Association functional classifications in patients with heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction.
• A study published in Experimental and therapeutic medicine 4 found that the combination of Furosemide and Spironolactone improved clinical symptoms and long-term prognosis in elderly patients with diastolic heart failure.
• A systematic review and meta-analysis published in Heart failure reviews 5 found that Azosemide and Torasemide caused a significant reduction in brain natriuretic peptide level, but no significant difference was found between Furosemide and other diuretics in terms of glomerular filtration rate, water extraction, and sodium excretion.
• A review published in the American journal of hypertension 6 found that Spironolactone reduces proteinuria beyond that provided by other renin angiotensin aldosterone inhibitors, and its relative potency is approximately 25 times that of Amiloride and 10 times that of Eplerenone.

Key Findings

• Spironolactone has non-diuretic effects that contribute to its benefit in heart failure patients 2.
• The combination of Furosemide and Spironolactone is effective in improving clinical symptoms and long-term prognosis in elderly patients with diastolic heart failure 4.
• The choice of diuretic is essential for successful management of heart failure and is mainly guided by patient clinical situations and the presence of other co-morbidities 5.
• Spironolactone has a higher relative potency than Amiloride and Eplerenone in reducing proteinuria 6.